Conflitos das dinâmicas de transformação urbana e ambiental à luz da ecologia da paisagem

Atualmente, a taxa de crescimento das cidades é um desafio global para assegurar espaços para habitação, demanda por serviços e lazer, e ao mesmo tempo garantir a manutenção e preservação de áreas verdes que compõe uma paisagem sustentável. Este estudo propõe o uso das análises das métricas de paisagem para guiar decisões, buscando identificar e caracterizar os fragmentos para selecionar unidades em condição para estabelecimentos de corredores em equilíbrio com a ocupação antrópica do território. Assim, a motivação deste artigo é revisitar os princípios do uso das métricas da paisagem, com o emprego de Sistemas de Informações Geográficas (SIG) e modelos de análise espacial em geoprocessamento uma vez que os resultados indicam que as métricas de forma e distribuição espacial são muito úteis para caracterização da ocupação antrópica em comparação à cobertura vegetal. A principal contribuição do trabalho é a tabela comparativa entre as métricas aplicadas aos fragmentos de manchas urbanas e aos fragmentos de cobertura vegetal. O processo é ilustrado através de um estudo de caso em uma importante paisagem caracterizada por conflitos de interesses, demonstrado a aplicação das métricas de paisagem e análise morfológica no planejamento regional. Ao revisitar os estudos de morfometrias (Ecologia da Paisagem) inova ao aplicar suas lógicas para os estudos de áreas urbanas e manchas urbanas, apresentando uma proposta de como identificar condições de dinamismo, avaliando cada fragmento urbano segundo sua condição de expansão, potencial de influenciar transformações no território ou de estabilidade em termos de transformação

A revista Espaço e Debates e as condições do debate sobre o urbano no Brasil

-Estuda-se a revista Espaço & Debates (E&D), entendendo-a como um espelho dos interesses que motivaram a reformulação do debate intelectual acerca do urbano no Brasil na fase pós-ditadura militar. A pesquisa tem sur referência metodológica na teoria dos campos sociais, desenvolvida por Pierre Bourdieu, a qual propõe entender, na forma de uma ciência, o processo de produção da própria ciência. Uma vez que a análise proposta pretende focar no campo intelectual do planejamento urbano, cujos modelos, métodos e processos são o objeto de trabalho, E&D aparece como a melhor opção para permitir uma radiografia da movimentação dos atores (corpo editorial, correspondentes, etc.) e autores que com ela contribuíram na abordagem multidisciplinar que caracteriza a trajetória da revista. Ao longo do trabalho foram desenvolvidas diversas estratégias de pesquisa que buscaram entender o acontecido na revista no recorte temporal proposto (um período de 15 anos a partir de seu lançamento, em 1981). Essas estratégias foram desenvolvidas (por vezes inclusive paralelamente) e tiveram como foco: 1) os atores (autores, editores, administradores), as relações acadêmicas que estabeleceram entre si e com instituições de ensino, pesquisa e planejamento, e os referenciais teóricos e bibliográficos que utilizaram; 2) a busca pela compreensão da dinâmica do corpo editorial, os fatores que influenciariam o processo de aprovação dos artigos e a verificação da presença ou não de privilegiações; 3) o reconhecimento do perfil de quem publica em E&D; 4) o alcance geográfico da revista, no qual estará focada a presente apresentação. Sabe-se que a revista teve um certo papel de mediadora entre o que era produzido nacional e internacionalmente através da publicação de artigos traduzidos, de referências ao debate internacional, e através das relações com outras revistas. Olhar para essas relações interinstitucionais, permitiu verificar quem reconhece E&D e por quem ela é reconhecida tanto ao redor do mundo quanto dentro do Brasil. Paralelamente, ao serem relacionadas informações sobre o perfil dos autores que submetem artigos para publicação em E&D, como por exemplo local de graduação e de trabalho nessa época, pode-se compreender a atenção que a revista recebia no país. Os dados coletados, tanto dos registros de E&D (livro tombo), das correspondências mantidas entre a revista e outros periódicos e dos currículo (Lattes) dos autores, permitiram construir mapas e dados estatísticos sobre os lugares de reconhecimento ou influência de E&D. Algumas conclusões e hipóteses foram possíveis elaborar a partir desses dados. Primeiramente, há um desequilíbrio na representatividade de estados e regiões na quantidade de artigos submetidos à análise ou aprovados para publicação, o que se relaciona à distribuição geográfica dos cursos de pós-graduação, uma vez que boa parte dos artigos é escrita no período em que os autores desenvolviam seus trabalhos nesses lugares. Estima-se que esse desequilíbrio também esteja relacionado com a concentração das ofertas de trabalho, já que há uma certa movimentação interestadual – principalmente em direção aos grandes centros, por natureza polarizadores do conhecimento – entre o momento da graduação dos autores e aquele em que submetem seus artigos

Sementes de Lágrima-de-Nossa-Senhora submetidas a diferentes tratamentos para superação de dormência / Tear-of-Our-Lady seeds submitted to different treatments to overcome dormancy

As informações disponíveis sobre as condições que favorecem o desempenho germinativo das sementes de Lágrima-de-Nossa-Senhora ainda são insuficientes. Assim, o objetivo foi avaliar a germinação de sementes de Coix lacryma-jobi sob diferentes tratamentos para a superação da dormência. Para isso, o trabalho foi dividido em três Ensaios. O Primeiro Ensaio, com os seguintes tratamentos: (i). imersão em solução com 300ml de ácido sulfúrico durante 25 minutos; (ii). imersão em água fervente por 10 minutos; (iii). excesso de água (50 ml, uma vez por semana) e; (iv). tratamento controle (água suficiente para umedecer as sementes e o papel). O Segundo Ensaio com os seguintes tratamentos: (i). controle (fornecimento normal de água); (ii). baixas temperaturas (sementes na geladeira durante uma semana); (iii). imersão em água por 12 horas; (iv); lixa + embebição; (v). embebição + lixamento; (vi). corte na horizontal com tesoura de poda + embebição; (vii). embebição + corte na horizontal com tesoura de poda.  O Terceiro Ensaio, com diferentes concentrações de ácido giberélico (GA): (i). 0 mg de GA (somente imersão água); (ii). 10 mg de GA; (iii). 20 mg de GA; e (iv) 50 mg GA, diluído em 500 ml de água destilada. Para o Primeiro Ensaio, a melhor porcentagem foi no controle e no Segundo Ensaio foi lixamento + embebição apresentou melhor resposta, seguido do corte + embebição; e embebição + lixamento. A aplicação do ácido giberélico foi mais eficaz na concentração de 50 mg. Dos três Ensaios, o melhor foi com aplicação de ácido giberélico. Dessa forma, mais estudos devem ser realizados para verificar outras formas de superação da dormência dessa semente

As particularidades clínicas da otite média: Clinical features of otitis media

A otite média é um processo inflamatório de evolução abrupta, acompanhado pelo quadro clínico típico de inflamação na orelha média, sendo sua incidência prevalente em crianças, culminando em leves repercussões clínicas, mas que deve ser adequadamente diagnosticada e tratada. Este evento clínico pode ser agudo, subagudo ou crônico com aparições típicas, evolução e manejo clínico diferenciados. O seguinte artigo é uma revisão narrativa de literatura que visa analisar a respeito das principais particularidades clínicas da Otite Média. Diante das informações coletadas, pode se elucidar que a otite média é o fator causal para implicações negativas e antibioticoterapia em crianças, logo é essencial medidas para diagnose precoce para evitar repercussões na saúde destes

Farmacologia clínica da doença de Parkinson: Clinical pharmacology of Parkinson's disease

As patologias neurodegenerativas cursam com depleção progressiva e irreversível dos neurônios existentes em regiões específicas do cérebro. A Doença de Parkinson (DP) é um protótipo, na qual o extravio neuronal do hipocampo e do córtex resulta em déficit de memória e disfunção cognitiva. O seguinte artigo objetivou descrever de modo narrativo as considerações clínicas da doença de Parkinson que justifiquem a ação farmacológica dos fármacos empregados em sua terapêutica. Atualmente, a intervenção farmacológica e a cirúrgica não são capazes de reverter o quadro clínico, mas evitam a progressão da morbimortalidade da DP. O tratamento é individual, baseado na reação específica, o quadro clínico, resposta farmacológica e aspectos socioeconômicos, ocupacionais e emocionais. A finalidade se baseia em perpetuar a autonomia e funcionalidade, o máximo de tempo possível. A escolha dos fármacos mais apropriados para cada paciente e o início do tratamento e o acompanhamento ao longo da evolução são etapas difíceis. Devido a cronicidade, o tratamento deve continuar por toda a vida, considerando que os fármacos e suas doses mudam com o tempo, o surgimento de efeitos adversos

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021. Methods: The GBD 2021 risk factor analysis used data from 54 561 total distinct sources to produce epidemiological estimates for 88 risk factors and their associated health outcomes for a total of 631 risk–outcome pairs. Pairs were included on the basis of data-driven determination of a risk–outcome association. Age-sex-location-year-specific estimates were generated at global, regional, and national levels. Our approach followed the comparative risk assessment framework predicated on a causal web of hierarchically organised, potentially combinative, modifiable risks. Relative risks (RRs) of a given outcome occurring as a function of risk factor exposure were estimated separately for each risk–outcome pair, and summary exposure values (SEVs), representing risk-weighted exposure prevalence, and theoretical minimum risk exposure levels (TMRELs) were estimated for each risk factor. These estimates were used to calculate the population attributable fraction (PAF; ie, the proportional change in health risk that would occur if exposure to a risk factor were reduced to the TMREL). The product of PAFs and disease burden associated with a given outcome, measured in disability-adjusted life-years (DALYs), yielded measures of attributable burden (ie, the proportion of total disease burden attributable to a particular risk factor or combination of risk factors). Adjustments for mediation were applied to account for relationships involving risk factors that act indirectly on outcomes via intermediate risks. Attributable burden estimates were stratified by Socio-demographic Index (SDI) quintile and presented as counts, age-standardised rates, and rankings. To complement estimates of RR and attributable burden, newly developed burden of proof risk function (BPRF) methods were applied to yield supplementary, conservative interpretations of risk–outcome associations based on the consistency of underlying evidence, accounting for unexplained heterogeneity between input data from different studies. Estimates reported represent the mean value across 500 draws from the estimate's distribution, with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values across the draws. Findings: Among the specific risk factors analysed for this study, particulate matter air pollution was the leading contributor to the global disease burden in 2021, contributing 8·0% (95% UI 6·7–9·4) of total DALYs, followed by high systolic blood pressure (SBP; 7·8% [6·4–9·2]), smoking (5·7% [4·7–6·8]), low birthweight and short gestation (5·6% [4·8–6·3]), and high fasting plasma glucose (FPG; 5·4% [4·8–6·0]). For younger demographics (ie, those aged 0–4 years and 5–14 years), risks such as low birthweight and short gestation and unsafe water, sanitation, and handwashing (WaSH) were among the leading risk factors, while for older age groups, metabolic risks such as high SBP, high body-mass index (BMI), high FPG, and high LDL cholesterol had a greater impact. From 2000 to 2021, there was an observable shift in global health challenges, marked by a decline in the number of all-age DALYs broadly attributable to behavioural risks (decrease of 20·7% [13·9–27·7]) and environmental and occupational risks (decrease of 22·0% [15·5–28·8]), coupled with a 49·4% (42·3–56·9) increase in DALYs attributable to metabolic risks, all reflecting ageing populations and changing lifestyles on a global scale. Age-standardised global DALY rates attributable to high BMI and high FPG rose considerably (15·7% [9·9–21·7] for high BMI and 7·9% [3·3–12·9] for high FPG) over this period, with exposure to these risks increasing annually at rates of 1·8% (1·6–1·9) for high BMI and 1·3% (1·1–1·5) for high FPG. By contrast, the global risk-attributable burden and exposure to many other risk factors declined, notably for risks such as child growth failure and unsafe water source, with age-standardised attributable DALYs decreasing by 71·5% (64·4–78·8) for child growth failure and 66·3% (60·2–72·0) for unsafe water source. We separated risk factors into three groups according to trajectory over time: those with a decreasing attributable burden, due largely to declining risk exposure (eg, diet high in trans-fat and household air pollution) but also to proportionally smaller child and youth populations (eg, child and maternal malnutrition); those for which the burden increased moderately in spite of declining risk exposure, due largely to population ageing (eg, smoking); and those for which the burden increased considerably due to both increasing risk exposure and population ageing (eg, ambient particulate matter air pollution, high BMI, high FPG, and high SBP). Interpretation: Substantial progress has been made in reducing the global disease burden attributable to a range of risk factors, particularly those related to maternal and child health, WaSH, and household air pollution. Maintaining efforts to minimise the impact of these risk factors, especially in low SDI locations, is necessary to sustain progress. Successes in moderating the smoking-related burden by reducing risk exposure highlight the need to advance policies that reduce exposure to other leading risk factors such as ambient particulate matter air pollution and high SBP. Troubling increases in high FPG, high BMI, and other risk factors related to obesity and metabolic syndrome indicate an urgent need to identify and implement interventions

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill & Melinda Gates Foundation